Psychedelics have been a mainstay for a millennia and appreciated in the counter-culture for decades. In 2020, whether consuming, investing, or both, mushrooms are having a moment.
PsychedeliTech, a ground-breaking new conference, incubator and discovery platform for psychedelic medicine will host Rick Doblin, Ph.D., Founder and Executive Director of the Multidisciplinary Association for Psychedelic Studies (MAPS) as the keynote speaker at the first-ever PsyTech Summit, a forum for psychedelic science, innovation and investment conference, in Israel.
The inaugural PsyTech conference will take place March 29-30, 2020 at the Hilton Hotel, on the Mediterranean Sea in Tel Aviv.
PsyTech is a division of iCAN: Israel-Cannabis, which together with CannaTech, its medical cannabis events platform, has been a global participant in education and innovation for cannabis therapeutics and products with conferences in London, Sydney, Hong Kong, Panama and Cape Town, to date.
Saul Kaye, iCAN founder and CEO, said, “Rick Doblin is an early pioneer and extremely effective advocate for the potential of psychedelics in the treatment of mental health disease and symptoms, including depression, anxiety disorders, and PTSD. We are thrilled he will join us at our first PsyTech Summit in Tel Aviv to share his enlightened vision and vast knowledge of the fast-developing therapeutic ecosystem that is about to explode as a wave of new information, research and consumer interest about psychedelics floods the market.”
For the first 30 years of MAPS’ dedicated research, there were virtually no for-profit psychedelic business opportunities, apart from a few ibogaine and ayahuasca clinics and mushroom sales in countries where the substances are legal.
Psychedelics have the potential to impact and improve mental health.
For-profit entities emerging in the field of psychedelics, such as Cybin with microdosed psilocybin products and MindMed with ibogaine, are directly due to the success of non-profit psychedelic therapy research and advocacy, including the lifelong work of MAPS and other advocates.
“The new psychedelic industry will need to focus on public benefit as well as profit in order to avoid a cultural backlash against these historically misunderstood substances,” cautions Doblin.”I am looking forward to discussing these important issues at PsyTech, Israel’s first summit focusing on the therapeutic potential of psychedelics,” he continued.
The global market for mental health medications was worth $88.3 billion in 2015, according to BCC Research.
Similar to the cannabis industry, psychedelics and medicinal mushrooms will require an ecosystem to effectively drive education, regulation, safety, investment, research and development.
These key issues, as well as personal stories of treatment, will be explored at PsyTech.
The topic of psychadelics is sparking worldwide mainstream interest. People who want to learn more about the companies developing the science of mushrooms can attend a conference in New York, prior to the upcoming one in Tel Aviv.
“This is an exciting new industry and it’s just starting to grow, which is why GMR is hosting a mini-conference on Psychedelics in New York,” says Debra Borchardt, Editor-In-Chief of Green Market Report.
The Economics of Psychedelic Investing takes place on January 24, 2020 in NYC.
For those who merely want to experience the effects of psychedelic mushrooms in a safe and welcoming environment, Irie Selkirk offers her guests a transformative psilocybin experience complete with farm-to-table meals and a psychotherapist on staff, at her retreat in Jamaica.
With conferences, nascent investment opportunities and staycations, magic mushrooms are going mainstream.